US Patent

US9085558 — Substituted indazole derivatives active as kinase inhibitors

Formulation · Assigned to Nerviano Medical Sciences SRL · Expires 2028-07-08 · 2y remaining

Vulnerability score 55/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects substituted indazole derivatives and their pharmaceutically acceptable salts, which are kinase inhibitors.

USPTO Abstract

Substituted indazole derivatives of formula (I) and pharmaceutically acceptable salts thereof, as defined in the specification; the compounds of the invention may be useful in therapy in the treatment of diseases associated with a deregulated protein kinase activity, like cancer.

Drugs covered by this patent

Patent Metadata

Patent number
US9085558
Jurisdiction
US
Classification
Formulation
Expires
2028-07-08
Drug substance claim
No
Drug product claim
Yes
Assignee
Nerviano Medical Sciences SRL
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.